The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Septacidin     N-[[2-(1,2-dihydroxyethyl)- 4,5-dihydroxy-6...

Synonyms: Spicamycin, AGN-PC-00M51P, AC1LAS34, NSC65104, LS-74710, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Spicamycin


High impact information on Spicamycin


Gene context of Spicamycin


Analytical, diagnostic and therapeutic context of Spicamycin


  1. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines. Lee, Y.S., Nishio, K., Ogasawara, H., Funayama, Y., Ohira, T., Saijo, N. Cancer Res. (1995) [Pubmed]
  2. Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen. Kamishohara, M., Kawai, H., Sakai, T., Uchida, T., Tsuruo, T., Otake, N. Cancer Chemother. Pharmacol. (1996) [Pubmed]
  3. Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein. Zhang, W.J., Ohnishi, K., Yoshida, H., Pan, L., Maksumova, L., Muratkhodjaev, F., Luo, J.M., Shigeno, K., Fujisawa, S., Naito, K., Nakamura, S., Shinjo, K., Takeshita, A., Ohno, R. Jpn. J. Cancer Res. (2000) [Pubmed]
  4. Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro. Burger, A.M., Kaur, G., Hollingshead, M., Fischer, R.T., Nagashima, K., Malspeis, L., Duncan, K.L., Sausville, E.A. Clin. Cancer Res. (1997) [Pubmed]
  5. A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design. Gadgeel, S.M., Boinpally, R.R., Heilbrun, L.K., Wozniak, A., Jain, V., Redman, B., Zalupski, M., Wiegand, R., Parchment, R., LoRusso, P.M. Investigational new drugs. (2003) [Pubmed]
  6. KRN5500, a novel antitumor agent, induces apoptosis or cell differentiation in HL-60 cells. Kawasaki, K., Murakami, T., Ita, M., Sasaki, K., Furukawa, S. Cytometry. (2000) [Pubmed]
  7. KRN5500 induces apoptosis (PCD) of myeloid leukemia cell lines and patient blasts. Stine, K.C., Warren, B.A., Saylors, R.L., Becton, D.L. Leuk. Res. (2000) [Pubmed]
  8. Structure-antitumor activity relationship of semi-synthetic Spicamycin derivatives. Sakai, T., Kawai, H., Kamishohara, M., Odagawa, A., Suzuki, A., Uchida, T., Kawasaki, T., Tsuruo, T., Otake, N. J. Antibiot. (1995) [Pubmed]
  9. Structure-antitumor activity relationship of semi-synthetic spicamycin analogues. Kamishohara, M., Kawai, H., Odagawa, A., Isoe, T., Mochizuki, J., Uchida, T., Hayakawa, Y., Seto, H., Tsuruo, T., Otake, N. J. Antibiot. (1993) [Pubmed]
  10. A water-soluble synthetic spicamycin derivative (San-Gly) decreases mechanical allodynia in a rodent model of neuropathic pain. DiLorenzo, L., Kobierski, L., Moore, K.A., Borsook, D. Neurosci. Lett. (2002) [Pubmed]
WikiGenes - Universities